RYTM at a glance
RHYTHM PHARMACEUTICALS, INC. (RYTM, SEC CIK 1649904) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RHYTHM PHARMACEUTICALS, INC. (RYTM) reported revenue of $189.8 million (up 45.8% from FY2024) and a net loss of $196.5 million. Diluted EPS was -$3.11.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding RHYTHM PHARMACEUTICALS, INC. (RYTM) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Shulman Joseph on November 18, 2026 of 45,921 shares at $119.90 per share.
- In the last 90 days, RYTM insiders reported 0 open-market purchases ($0) and 12 open-market sales ($18.4M) on Form 4, a net sale of $18.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $189.8M
- +45.8% vs prior year
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$18.4M
- 13F holders
- 32 funds
- $2.6B · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of MC4R agonist therapies to treat rare neuroendocrine diseases causing severe obesity and hyperphagia
- New product focus: Anticipated 2026 US launch of IMCIVREE for acquired hypothalamic obesity, plus Phase 3 trial initiation for oral MC4R agonist bivamelagon
- Strategic shift: Expanded pipeline with second-generation MC4R agonists (bivamelagon, RM-718) and emphasis on congenital hypothalamic obesity and Prader-Willi syndrome (PWS)
- Quantitative highlight: 414 employees globally as of February 2026; Phase 3 EMANATE trial topline data expected March 2026 across four rare MC4R genetic disorders
- Noteworthy fact: IMCIVREE approved in 25+ countries; pivotal Phase 3 trial shows 19.8% placebo-adjusted BMI reduction in acquired hypothalamic obesity, addressing a 10,000-patient US population unmet need
Risk Factors
- Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
- Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase
- Operational risk from early-stage commercial manufacturing scale-up or reliance on third-party manufacturers for setmelanotide
- Competitive risk from other MC4R pathway therapies and development of RM-718 and bivamelagon, new selective MC4R agonists in clinical trials
- Financial risk from $100M Revenue Interest Financing Agreement requiring up to 11.5% royalties on first $125M net revenues, with payment obligations through 2029
Management Discussion & Analysis
- Revenue $422.5M to date from IMCIVREE product sales; commercial launch in US Q1 2021, France March 2022, ongoing growth expected
- Net loss $196.5M in 2025 vs $260.6M in 2024; operating expenses increased with R&D down to $167.3M from $238M, SG&A up to $194.9M from $144.3M
- R&D expenses $167.3M in 2025, decreased from $237.9M in 2024; SG&A expenses $194.9M in 2025, increased from $144.3M in 2024
- Cash and short-term investments approx. $388.9M as of Dec 31, 2025; expected to fund operations for at least 24 months; no specific buybacks or dividends disclosed
- Forward outlook: FDA PDUFA date for bivamelagon in acquired HO March 20, 2026; topline EMANATE Phase 3 data expected March 2026; expansion into PWS and Japan markets anticipated
AI summary of the RYTM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added financing risk: November 2, 2026 A&R RIFA and up to $750.0 million term loan introduced additional repayment and covenant obligations
- Most materially updated financial risk: RIFA amendment and term loan could restrict financing, acquisitions, asset sales and other operations
- Regulatory risk: EU IVDR class C companion diagnostics transition deadline reached May 26, 2026
- Operational risk: reliance on specialty pharmacy for significant U.S. revenue makes distributor transitions capable of reducing revenue and cash flows
- Financial risk: $320.9 million cash and investments, with uninsured deposits exposed to financial-institution failure
Management Discussion & Analysis
- Q3 revenue $92.1M, up 80% YoY from $51.3M, driven by higher domestic and international IMCIVREE volume
- Net loss $41.4M vs $52.9M; operating loss $39.3M vs $52.7M
- U.S. IMCIVREE revenue $67.5M, 73% of product revenue; ex-U.S. revenue $24.7M
- Cash, equivalents and short-term investments $320.9M; operating cash use $56.4M for nine months vs $90.3M
- Outlook: bivamelagon Phase 3 initiation by year-end 2026; $350.0M LGC obligation and term-loan access up to $750.0M increasing fixed obligations
AI summary of the RYTM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter fiscal 2026 results announced for the period ended September 30, 2026
- Full financial results available in furnished Exhibit 99.1, the company’s accompanying press release
Item EX-99.1: Item EX-99.1
- Q3 product revenue $92.1M, up 29% sequentially and 80% year over year, signaling accelerating IMCIVREE commercialization
- Acquired HO launch generated 700+ U.S. patient start forms from 500+ prescribers by September 30
Item EX-99.2: Item EX-99.2
- Q3 2026 net product revenue $92.1M, up from $51.3M, with 73% generated in the U.S.
- IMCIVREE revenue increased 29% QoQ, supported by U.S. acquired hypothalamic obesity launch and 20% growth in reimbursed patients
Item 8.01: Other Events
- Preliminary Phase 2 data: RM-718 reduced mean BMI 11.6% at 16 weeks in acquired hypothalamic obesity patients
- Efficacy comparable to bivamelagon and setmelanotide benchmarks, each showing 10.1% mean BMI reduction
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor-relevant operating metrics and financial details contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Preliminary Phase 2 RM-718 data announced for acquired hypothalamic obesity
- Presentation available through Rhythm Pharmaceuticals’ Events and Presentations webpage
Item EX-99.3: Item EX-99.3
- Q2 2026 product revenue $71.3M, up from $48.5M, with 19% sequential growth and 72% from the U.S.
- IMCIVREE launch exceeded 400 patient start forms and reached approximately 300 prescribers by June 30, 2026
Item EX-99.1: Item EX-99.1
- Q2 IMCIVREE revenue $71.3M, up 19% sequentially, signaling accelerating commercial adoption
- U.S. revenue $51.0M, up 38% sequentially, with 400+ acquired-HO start forms from approximately 300 prescribers
Item EX-99.2: Item EX-99.2
- RM-718 produced an encouraging -11.6% mean BMI reduction at Week 16, based on 7 patients with acquired hypothalamic obesity
- Efficacy broadly matched bivamelagon and setmelanotide comparators, each showing a -10.1% BMI reduction
Item 5.07: Submission of Matters to a Vote of Security Holders
- 92% turnout: 64,146,146 of 69,675,938 eligible votes represented
- David W. J. McGirr and David P. Meeker, MD elected as Class III directors through 2029
AI summaries of RYTM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RYTM
Don't miss the next RYTM filing
- Alerts as it files. A push when RYTM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RYTM, by share count.
- Ask anything. An AI agent that reads every RYTM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shulman Joseph | M | Nov 18, 2026 | 24,944 | - |
| Shulman Joseph | M | Nov 18, 2026 | 9,374 | - |
| Shulman Joseph | M | Nov 18, 2026 | 1,961 | - |
| Shulman Joseph | M | Nov 18, 2026 | 4,188 | - |
| Shulman Joseph | M | Nov 18, 2026 | 9,374 | $56.69 |
| Shulman Joseph | M | Nov 18, 2026 | 24,944 | $49.23 |
| Shulman Joseph | M | Nov 18, 2026 | 4,188 | $27.35 |
| Shulman Joseph | Sell | Nov 18, 2026 | 45,921 | $119.90 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $130.1M | $189.8M |
| Operating Income | - | -$265.5M | -$192.0M |
| Net Income | -$184.7M | -$260.6M | -$196.5M |
| Op. Margin | - | -204.0% | -101.2% |
| Net Margin | - | -200.3% | -103.6% |
| Balance Sheet | |||
| Total Assets | $332.7M | $392.3M | $480.2M |
| Equity | - | $21.7M | $139.1M |
| ROE | - | -1199.3% | -141.3% |
| Per Share | |||
| EPS | $-3.20 | $-4.34 | $-3.11 |
| Cash Flow | |||
| Operating CF | - | -$113.9M | -$115.7M |
| CapEx | $47K | $0 | $953K |
Source: XBRL data in RHYTHM PHARMACEUTICALS, INC. (RYTM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RYTM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $2.65B |
| Q2 2026 | 33 | $3.24B |
| Q1 2026 | 32 | $2.36B |
| Q4 2025 | 27 | $2.62B |
| Q3 2025 | 27 | $2.48B |
| Q2 2025 | 26 | $1.30B |
| Q1 2025 | 23 | $608.8M |
| Q4 2024 | 19 | $396.6M |
- JPMorgan Chase & Co+905.5K (+34%)
- Invesco Ltd+120.2K (+22%)
- State Street Corp+65.2K (+3%)
- Bank of America Corp+38.7K (+12%)
- Renaissance Technologies LLC+20.4K (+30%)
- Citadel Advisors LLC−946.7K (-75%)
- T. Rowe Price Group−231.2K (-9%)
- Morgan Stanley−199.2K (-18%)
- BlackRock−181.6K (-3%)
- Ameriprise Financial−90.1K (-22%)
- FMR LLC (Fidelity)−1.03M
- Allstate−4.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RYTM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RYTM SEC filings: frequently asked questions
Are RYTM insiders buying or selling?
In the last 90 days, RHYTHM PHARMACEUTICALS, INC. (RYTM) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $18.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RYTM stock?
As of September 30, 2026, the largest RHYTHM PHARMACEUTICALS, INC. (RYTM) holders among the 13F filers tracked by SignalX were BlackRock ($568.9 million), JPMorgan Chase & Co ($340.8 million), Vanguard Portfolio Management LLC ($299.8 million), Vanguard Capital Management LLC ($286.2 million), State Street Corp ($251.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RYTM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RHYTHM PHARMACEUTICALS, INC. (RYTM) reported revenue of $189.8 million (up 45.8% from FY2024) and a net loss of $196.5 million. Diluted EPS was -$3.11. The figures come from the XBRL data in the 10-K.
What are the main risks in RYTM's latest 10-K?
In the 10-K filed February 26, 2026, RHYTHM PHARMACEUTICALS, INC. (RYTM) flagged: Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch. Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase. (AI summary of the Risk Factors section.)
What did RYTM report in its latest 8-K?
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter fiscal 2026 results announced for the period ended September 30, 2026.
What are the latest RYTM SEC filings?
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 20, 2026.
What is RYTM's SEC CIK number?
RHYTHM PHARMACEUTICALS, INC. (RYTM)'s SEC Central Index Key (CIK) is 1649904. EDGAR lists every RYTM filing under that number.
Ask anything about RYTM
The research agent reads RYTM's filings, financials, insider trades and 13F holders, then answers with sources.